NCT02061878View on ClinicalTrials.gov

A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Alzheimer's Disease
Interventions
DRUG

Bexarotene

Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.

DRUG

Placebo

The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.

Trial Locations (1)

32806

Compass Research, Orlando

All Listed Sponsors
lead

ReXceptor, Inc.

INDUSTRY

NCT02061878 - A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects | Biotech Hunter | Biotech Hunter